{"success":true,"data":{"pressRelease":{"id":"18629","rtpr_id":"nBw9hKDla","ticker":"PODD","exchange":"NASDAQ","all_tickers":["PODD"],"title":"Insulet Initiates EVOLVE Pivotal Study to Advance Fully Closed-Loop Automated Insulin Delivery System for Type 2 Diabetes","author":"Business Wire","published_at":"2026-05-04T11:00:00.470Z","article_body":"Insulet Initiates EVOLVE Pivotal Study to Advance Fully Closed-Loop Automated\nInsulin Delivery System for Type 2 Diabetes\n\n\n * First participant enrolled in randomized control trial designed to demonstrate\nsafety and efficacy of Insulet’s fully closed-loop automated insulin\ndelivery system versus standard therapy\n\n * Unique algorithm automatically adjusts insulin delivery, eliminating mealtime\ninteraction and redefining the healthcare provider experience\n\nInsulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader\nin tubeless insulin pump technology\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.omnipod.com%2F&esheet=54527079&newsitemid=20260504714368&lan=en-US&anchor=tubeless+insulin+pump+technology&index=1&md5=5c5c0c19f5457e31255f2102a6e7b836)\nwith its Omnipod(®) brand of products, has enrolled the first participant in\na pivotal study for its fully closed-loop (FCL)(A) automated insulin delivery\n(AID) system for type 2 diabetes (T2D). FCL for T2D is a breakthrough\ninnovation intended to further improve glycemic outcomes with less burden for\nusers across diverse care settings. That includes eliminating user\ninteractions for bolusing and mealtime announcements for people with T2D as\nwell as settings to start and onboard.\n\n“Our innovation strategy is grounded in empathy and steadfast in our mission\nto transform the lives of people with diabetes,” said Dr. Trang Ly, Senior\nVice President and Chief Medical Officer at Insulet. “Enrolling the first\nEVOLVE study participant marks an important step toward a fully closed‑loop\nAID system. Powered by a novel algorithm trained on extensive real and\nsimulated patient data to safely titrate dosing and automatically adjust\ninsulin delivery, our fully closed-loop AID system is uniquely designed to\nfurther reduce the burden for people with type 2 diabetes and their care\nteams.”\n\nAdvancing AID Through a Fully Closed Loop System\n\nThe EVOLVE clinical study is a multi-center randomized control trial actively\nenrolling up to 350 adults across a maximum of 40 U.S. sites. The participants\nare between 18 – 75 years of age, living with T2D and using insulin\n(basal-bolus or basal-only). The Company received Investigational Device\nExemption (IDE) approval in March 2026 from the U.S. Food and Drug\nAdministration (FDA).\n\nThe Company aims to remove barriers and expand access to AID, particularly in\nprimary care, where approximately 70% of people with T2D are managed. By\nstreamlining onboarding and training and eliminating start‑up settings,\nInsulet’s FCL for T2D is designed to reduce workload and support healthcare\nprofessionals across specialties and care settings.\n\nThe EVOLVE( D) Pivotal Study follows a three-part series of feasibility\nstudies to support the development of Insulet’s FCL AID system. The Company\npresented promising feasibility results\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestors.insulet.com%2Fnews%2Fnews-details%2F2026%2FInsulet-Presents-Promising-Study-Results-for-Fully-Closed-Loop-Automated-Insulin-Delivery-System-for-Adults-with-Type-2-Diabetes%2Fdefault.aspx&esheet=54527079&newsitemid=20260504714368&lan=en-US&anchor=promising+feasibility+results&index=2&md5=c46383bada4a4ef0b49dd128087884d8)\nat the 19(th) International Conference on Advanced Technologies &\nTreatments for Diabetes (ATTD) in Barcelona, Spain, including a 24% time in\nrange (TIR) improvement, for an average of 68%, over standard injection\ntherapy.\n\nDelivering Meaningful Impact Today While Innovating for Tomorrow\n\nIn 2024, Insulet shared results from its landmark SECURE-T2D\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestors.insulet.com%2Fnews%2Fnews-details%2F2024%2FInsulets-SECURE-T2D-Pivotal-Trial-Results-Demonstrate-Omnipod-5-Improves-Clinical-Outcomes-and-Quality-of-Life-in-Type-2-Diabetes%2Fdefault.aspx&esheet=54527079&newsitemid=20260504714368&lan=en-US&anchor=SECURE-T2D&index=3&md5=8c5525c06584e227fa53abef8b9caf98)\npivotal trial, demonstrating improved glycemic outcomes with Omnipod 5\ncompared with prior insulin injection or pump therapy in adults with T2D.\nParticipants experienced a reduction in HbA1c from 8.2% to 7.4% and a 20%\nincrease in TIR– from 45% to 66% or 4.8 hours daily.\n\nWith these results, Insulet was the first company to receive 510(k) clearance\nfor an AID system, Omnipod 5, for adults with T2D. Since then, the Company has\nseen impressive adoption rates and real-world evidence of glycemic\nimprovements including more than 80% TIR with optimized settings for people\nwith T2D using Omnipod 5( E).\n\nWhile Insulet’s type 2 prescriber base in the U.S. grew by more than 60% in\n2025 to more than 6,500 clinicians, AID adoption remains well below 5% for the\nestimated 5.5 million people with T2D who require insulin. Insulet is\ncommitted to continuing to expand adoption of AID for this population, as\nrecommended by the American Diabetes Association’s 2026 Standards of Care.\n\nThe Company plans to submit a 510(k) filing to the FDA in 2027 and launch its\nFCL AID system for T2D in 2028.\n\n(A) The FCL AID System is an investigational device. Limited by Federal (or\nUnited States) law to investigational use. This product has not been reviewed\nby the FDA or any other regulatory agency.\n\n(B) Venkatraman S, et al. Trends and Disparities in Glycemic Control and\nSevere Hyperglycemia Among U.S. Adults with Diabetes Using Insulin,\n1988-22020. JAMA Netw Open. 2022 Dec 1;5(12). The EVOLVE study will evaluate a\nnew fully closed-looped AID system for Type 2 diabetes.\n\n(C) Pilla, S.J., Segal, J.B. & Maruthur, N.M. Primary Care Provides the\nMajority of Outpatient Care for Patients with Diabetes in the US: NAMCS\n2009–2015. J GEN INTERN MED 34, 1089–1091 (2019).\nhttps://doi.org/10.1007/s11606-019-04843-9\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fdoi.org%2F10.1007%2Fs11606-019-04843-9&esheet=54527079&newsitemid=20260504714368&lan=en-US&anchor=https%3A%2F%2Fdoi.org%2F10.1007%2Fs11606-019-04843-9&index=4&md5=46c2c95cd5b255668f9d7bc5af6f4215)\n\n(D) https://clinicaltrials.gov/study/NCT07521475\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07521475&esheet=54527079&newsitemid=20260504714368&lan=en-US&anchor=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07521475&index=5&md5=b6eb98a25969e794eeb6c7d6de0a5c86)\n\n(E )Retrospective RWE data on file. 2025. Results shown for T2D users with\noptimized settings including sufficient CGM data (≥75% of days with ≥220\nreadings), ≥90% time in Automated Mode, ≥3 bolus/day and an average Target\nGlucose of 110-115 mg/dL (6.1-6.4 mmol/L). Optimized settings: ISF x TDI\n≤1500, I:C Ratio x TDI ≤350. RF-062025-00014.\n\nAbout Insulet Corporation:\n\nInsulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an\ninnovative medical device company dedicated to simplifying life for people\nwith diabetes and other conditions through its Omnipod product platform. The\nOmnipod Insulin Management System provides a unique alternative to traditional\ninsulin delivery methods. With its simple, wearable design, the tubeless\ndisposable Pod provides up to three days of non-stop insulin delivery, without\nthe need to see or handle a needle. Insulet’s flagship innovation, the\nOmnipod 5 Automated Insulin Delivery System, integrates with a continuous\nglucose monitor to manage blood sugar with no multiple daily injections, zero\nfingersticks, and can be controlled by a compatible personal smartphone in the\nU.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design\nof its Pod by tailoring its Omnipod technology platform for the delivery of\nnon-insulin subcutaneous drugs across other therapeutic areas. For more\ninformation visit: insulet.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.insulet.com%2F&esheet=54527079&newsitemid=20260504714368&lan=en-US&anchor=insulet.com&index=6&md5=cd0e9c08cffca967fcadf60e2325a52b)\nand omnipod.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.omnipod.com%2F&esheet=54527079&newsitemid=20260504714368&lan=en-US&anchor=omnipod.com&index=7&md5=01a4c32ecae31a367c1a92d7a08776cf)\n.\n\n©2026 Insulet Corporation. Omnipod is a registered trademark of Insulet\nCorporation in the United States of America and other various jurisdictions.\nAll rights reserved.\n\nForward-Looking Statement:\n\nThis press release may contain forward-looking statements concerning Insulet's\nexpectations, anticipations, intentions, beliefs, or strategies regarding the\nfuture. These forward-looking statements are based on its current expectations\nand beliefs concerning future developments and their potential effects on\nInsulet. There can be no assurance that future developments affecting Insulet\nwill be those that it has anticipated. These forward-looking statements\ninvolve a number of risks, uncertainties (some of which are beyond its\ncontrol) or other assumptions that may cause actual results or performance to\nbe materially different from those expressed or implied by these\nforward-looking statements, and other risks and uncertainties described in its\nAnnual Report on Form 10-K, which was filed with the Securities and Exchange\nCommission on February 21, 2025 in the section entitled \"Risk Factors,\" and in\nits other filings from time to time with the Securities and Exchange\nCommission. Should one or more of these risks or uncertainties materialize, or\nshould any of its assumptions prove incorrect, actual results may vary\nmaterially from those projected in these forward-looking statements. Insulet\nundertakes no obligation to publicly update or revise any forward-looking\nstatements.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260504714368/en/\n(https://www.businesswire.com/news/home/20260504714368/en/)\n\nInvestor Relations: \n\nClare Trachtman \n\nVice President, Investor Relations \n\nir@insulet.com (mailto:ir@insulet.com)  \n\nMedia: \n\nCristal Downing \n\nChief Corporate Affairs Officer \n\npr@insulet.com (mailto:pr@insulet.com)  \n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw9hKDla","title":"Insulet Initiates EVOLVE Pivotal Study to Advance Fully Closed-Loop Automated Insulin Delivery System for Type 2 Diabetes","author":"Business Wire","ticker":"PODD","created":"2026-05-04T11:00:00.470Z","tickers":["PODD"],"exchange":"NASDAQ","article_body":"Insulet Initiates EVOLVE Pivotal Study to Advance Fully Closed-Loop Automated\nInsulin Delivery System for Type 2 Diabetes\n\n\n * First participant enrolled in randomized control trial designed to demonstrate\nsafety and efficacy of Insulet’s fully closed-loop automated insulin\ndelivery system versus standard therapy\n\n * Unique algorithm automatically adjusts insulin delivery, eliminating mealtime\ninteraction and redefining the healthcare provider experience\n\nInsulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader\nin tubeless insulin pump technology\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.omnipod.com%2F&esheet=54527079&newsitemid=20260504714368&lan=en-US&anchor=tubeless+insulin+pump+technology&index=1&md5=5c5c0c19f5457e31255f2102a6e7b836)\nwith its Omnipod(®) brand of products, has enrolled the first participant in\na pivotal study for its fully closed-loop (FCL)(A) automated insulin delivery\n(AID) system for type 2 diabetes (T2D). FCL for T2D is a breakthrough\ninnovation intended to further improve glycemic outcomes with less burden for\nusers across diverse care settings. That includes eliminating user\ninteractions for bolusing and mealtime announcements for people with T2D as\nwell as settings to start and onboard.\n\n“Our innovation strategy is grounded in empathy and steadfast in our mission\nto transform the lives of people with diabetes,” said Dr. Trang Ly, Senior\nVice President and Chief Medical Officer at Insulet. “Enrolling the first\nEVOLVE study participant marks an important step toward a fully closed‑loop\nAID system. Powered by a novel algorithm trained on extensive real and\nsimulated patient data to safely titrate dosing and automatically adjust\ninsulin delivery, our fully closed-loop AID system is uniquely designed to\nfurther reduce the burden for people with type 2 diabetes and their care\nteams.”\n\nAdvancing AID Through a Fully Closed Loop System\n\nThe EVOLVE clinical study is a multi-center randomized control trial actively\nenrolling up to 350 adults across a maximum of 40 U.S. sites. The participants\nare between 18 – 75 years of age, living with T2D and using insulin\n(basal-bolus or basal-only). The Company received Investigational Device\nExemption (IDE) approval in March 2026 from the U.S. Food and Drug\nAdministration (FDA).\n\nThe Company aims to remove barriers and expand access to AID, particularly in\nprimary care, where approximately 70% of people with T2D are managed. By\nstreamlining onboarding and training and eliminating start‑up settings,\nInsulet’s FCL for T2D is designed to reduce workload and support healthcare\nprofessionals across specialties and care settings.\n\nThe EVOLVE( D) Pivotal Study follows a three-part series of feasibility\nstudies to support the development of Insulet’s FCL AID system. The Company\npresented promising feasibility results\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestors.insulet.com%2Fnews%2Fnews-details%2F2026%2FInsulet-Presents-Promising-Study-Results-for-Fully-Closed-Loop-Automated-Insulin-Delivery-System-for-Adults-with-Type-2-Diabetes%2Fdefault.aspx&esheet=54527079&newsitemid=20260504714368&lan=en-US&anchor=promising+feasibility+results&index=2&md5=c46383bada4a4ef0b49dd128087884d8)\nat the 19(th) International Conference on Advanced Technologies &\nTreatments for Diabetes (ATTD) in Barcelona, Spain, including a 24% time in\nrange (TIR) improvement, for an average of 68%, over standard injection\ntherapy.\n\nDelivering Meaningful Impact Today While Innovating for Tomorrow\n\nIn 2024, Insulet shared results from its landmark SECURE-T2D\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestors.insulet.com%2Fnews%2Fnews-details%2F2024%2FInsulets-SECURE-T2D-Pivotal-Trial-Results-Demonstrate-Omnipod-5-Improves-Clinical-Outcomes-and-Quality-of-Life-in-Type-2-Diabetes%2Fdefault.aspx&esheet=54527079&newsitemid=20260504714368&lan=en-US&anchor=SECURE-T2D&index=3&md5=8c5525c06584e227fa53abef8b9caf98)\npivotal trial, demonstrating improved glycemic outcomes with Omnipod 5\ncompared with prior insulin injection or pump therapy in adults with T2D.\nParticipants experienced a reduction in HbA1c from 8.2% to 7.4% and a 20%\nincrease in TIR– from 45% to 66% or 4.8 hours daily.\n\nWith these results, Insulet was the first company to receive 510(k) clearance\nfor an AID system, Omnipod 5, for adults with T2D. Since then, the Company has\nseen impressive adoption rates and real-world evidence of glycemic\nimprovements including more than 80% TIR with optimized settings for people\nwith T2D using Omnipod 5( E).\n\nWhile Insulet’s type 2 prescriber base in the U.S. grew by more than 60% in\n2025 to more than 6,500 clinicians, AID adoption remains well below 5% for the\nestimated 5.5 million people with T2D who require insulin. Insulet is\ncommitted to continuing to expand adoption of AID for this population, as\nrecommended by the American Diabetes Association’s 2026 Standards of Care.\n\nThe Company plans to submit a 510(k) filing to the FDA in 2027 and launch its\nFCL AID system for T2D in 2028.\n\n(A) The FCL AID System is an investigational device. Limited by Federal (or\nUnited States) law to investigational use. This product has not been reviewed\nby the FDA or any other regulatory agency.\n\n(B) Venkatraman S, et al. Trends and Disparities in Glycemic Control and\nSevere Hyperglycemia Among U.S. Adults with Diabetes Using Insulin,\n1988-22020. JAMA Netw Open. 2022 Dec 1;5(12). The EVOLVE study will evaluate a\nnew fully closed-looped AID system for Type 2 diabetes.\n\n(C) Pilla, S.J., Segal, J.B. & Maruthur, N.M. Primary Care Provides the\nMajority of Outpatient Care for Patients with Diabetes in the US: NAMCS\n2009–2015. J GEN INTERN MED 34, 1089–1091 (2019).\nhttps://doi.org/10.1007/s11606-019-04843-9\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fdoi.org%2F10.1007%2Fs11606-019-04843-9&esheet=54527079&newsitemid=20260504714368&lan=en-US&anchor=https%3A%2F%2Fdoi.org%2F10.1007%2Fs11606-019-04843-9&index=4&md5=46c2c95cd5b255668f9d7bc5af6f4215)\n\n(D) https://clinicaltrials.gov/study/NCT07521475\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07521475&esheet=54527079&newsitemid=20260504714368&lan=en-US&anchor=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07521475&index=5&md5=b6eb98a25969e794eeb6c7d6de0a5c86)\n\n(E )Retrospective RWE data on file. 2025. Results shown for T2D users with\noptimized settings including sufficient CGM data (≥75% of days with ≥220\nreadings), ≥90% time in Automated Mode, ≥3 bolus/day and an average Target\nGlucose of 110-115 mg/dL (6.1-6.4 mmol/L). Optimized settings: ISF x TDI\n≤1500, I:C Ratio x TDI ≤350. RF-062025-00014.\n\nAbout Insulet Corporation:\n\nInsulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an\ninnovative medical device company dedicated to simplifying life for people\nwith diabetes and other conditions through its Omnipod product platform. The\nOmnipod Insulin Management System provides a unique alternative to traditional\ninsulin delivery methods. With its simple, wearable design, the tubeless\ndisposable Pod provides up to three days of non-stop insulin delivery, without\nthe need to see or handle a needle. Insulet’s flagship innovation, the\nOmnipod 5 Automated Insulin Delivery System, integrates with a continuous\nglucose monitor to manage blood sugar with no multiple daily injections, zero\nfingersticks, and can be controlled by a compatible personal smartphone in the\nU.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design\nof its Pod by tailoring its Omnipod technology platform for the delivery of\nnon-insulin subcutaneous drugs across other therapeutic areas. For more\ninformation visit: insulet.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.insulet.com%2F&esheet=54527079&newsitemid=20260504714368&lan=en-US&anchor=insulet.com&index=6&md5=cd0e9c08cffca967fcadf60e2325a52b)\nand omnipod.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.omnipod.com%2F&esheet=54527079&newsitemid=20260504714368&lan=en-US&anchor=omnipod.com&index=7&md5=01a4c32ecae31a367c1a92d7a08776cf)\n.\n\n©2026 Insulet Corporation. Omnipod is a registered trademark of Insulet\nCorporation in the United States of America and other various jurisdictions.\nAll rights reserved.\n\nForward-Looking Statement:\n\nThis press release may contain forward-looking statements concerning Insulet's\nexpectations, anticipations, intentions, beliefs, or strategies regarding the\nfuture. These forward-looking statements are based on its current expectations\nand beliefs concerning future developments and their potential effects on\nInsulet. There can be no assurance that future developments affecting Insulet\nwill be those that it has anticipated. These forward-looking statements\ninvolve a number of risks, uncertainties (some of which are beyond its\ncontrol) or other assumptions that may cause actual results or performance to\nbe materially different from those expressed or implied by these\nforward-looking statements, and other risks and uncertainties described in its\nAnnual Report on Form 10-K, which was filed with the Securities and Exchange\nCommission on February 21, 2025 in the section entitled \"Risk Factors,\" and in\nits other filings from time to time with the Securities and Exchange\nCommission. Should one or more of these risks or uncertainties materialize, or\nshould any of its assumptions prove incorrect, actual results may vary\nmaterially from those projected in these forward-looking statements. Insulet\nundertakes no obligation to publicly update or revise any forward-looking\nstatements.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260504714368/en/\n(https://www.businesswire.com/news/home/20260504714368/en/)\n\nInvestor Relations: \n\nClare Trachtman \n\nVice President, Investor Relations \n\nir@insulet.com (mailto:ir@insulet.com)  \n\nMedia: \n\nCristal Downing \n\nChief Corporate Affairs Officer \n\npr@insulet.com (mailto:pr@insulet.com)  \n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-05-04T11:00:00.514762309Z","server_sent_at_ms":1777892400514},"received_at":"2026-05-04T11:00:00.576Z","source_url":"https://www.businesswire.com/news/home/20260504714368/en/"},"analysis":{"id":"13419","press_release_id":"18629","analysis_json":{"industry":{"label":"Health Care Equipment & Services","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Insulet initiated the EVOLVE pivotal study for its fully closed-loop automated insulin delivery system targeting Type 2 diabetes, enrolling the first participant in a trial aiming to demonstrate safety and efficacy.\n\nThe multi-center randomized control trial plans to enroll up to 350 adults across 40 U.S. sites, following Investigational Device Exemption approval received from the FDA in March 2026.\n\nThe company targets a 510(k) submission in 2027 and a commercial launch in 2028, aiming to expand automated insulin delivery access to primary care settings where 70% of T2D patients are managed.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Pivotal trial initiation for fully closed-loop system in Type 2 diabetes expands market opportunity."},"keyFigures":{"phaseOfTrial":"Pivotal","customDimensions":{"filing_year":2027,"launch_year":2028,"study_sites":40,"target_enrollment":350,"tir_increase_secure_t2d":"20% (45% to 66%)","hba1c_reduction_secure_t2d":"8.2% to 7.4%","tir_improvement_feasibility":"24%"}},"quotedText":"Enrolling the first EVOLVE study participant marks an important step toward a fully closed‑loop AID system.","namedEntities":{"people":[{"name":"Dr. Trang Ly","role":"Senior Vice President and Chief Medical Officer"},{"name":"Clare Trachtman","role":"Vice President, Investor Relations"},{"name":"Cristal Downing","role":"Chief Corporate Affairs Officer"}],"products":["Omnipod","Omnipod 5 Automated Insulin Delivery System","fully closed-loop (FCL) automated insulin delivery (AID) system"],"companies":[{"name":"Insulet Corporation","ticker":"PODD"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Initiation of a pivotal study (EVOLVE) for a fully closed-loop automated insulin delivery system expands the addressable market to Type 2 diabetes. While a significant milestone, regulatory submission is not expected until 2027, making it a medium-term catalyst rather than an immediate binary event."},"tickerRelevance":{"others":[],"primary":"PODD"},"globalImportance":35,"audienceRelevance":30,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"pivotal_trial_initiation","sectorWeight":"health_care_devices","marketExpansion":"Type_2_Diabetes_entry"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Insulet initiated the EVOLVE pivotal study for its fully closed-loop automated insulin delivery system targeting Type 2 diabetes, enrolling the first participant in a trial aiming to demonstrate safety and efficacy.\n\nThe multi-center randomized control trial plans to enroll up to 350 adults across 40 U.S. sites, following Investigational Device Exemption approval received from the FDA in March 2026.\n\nThe company targets a 510(k) submission in 2027 and a commercial launch in 2028, aiming to expand automated insulin delivery access to primary care settings where 70% of T2D patients are managed.","key_figures":{"phaseOfTrial":"Pivotal","customDimensions":{"filing_year":2027,"launch_year":2028,"study_sites":40,"target_enrollment":350,"tir_increase_secure_t2d":"20% (45% to 66%)","hba1c_reduction_secure_t2d":"8.2% to 7.4%","tir_improvement_feasibility":"24%"}},"named_entities":{"people":[{"name":"Dr. Trang Ly","role":"Senior Vice President and Chief Medical Officer"},{"name":"Clare Trachtman","role":"Vice President, Investor Relations"},{"name":"Cristal Downing","role":"Chief Corporate Affairs Officer"}],"products":["Omnipod","Omnipod 5 Automated Insulin Delivery System","fully closed-loop (FCL) automated insulin delivery (AID) system"],"companies":[{"name":"Insulet Corporation","ticker":"PODD"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:a2703c5a1b5285fe","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-05-04T11:01:17.953Z","global_importance":35,"audience_relevance":30,"importance_components":{"tickerTier":"mid-cap","eventGravity":"pivotal_trial_initiation","sectorWeight":"health_care_devices","marketExpansion":"Type_2_Diabetes_entry"}},"durationMs":23723,"modelName":"glm-4.7"}}